Literature DB >> 34410385

Accounting for country- and time-specific values in the economic evaluation of health-related projects relevant to low- and middle-income countries.

James Lomas, Karl Claxton, Jessica Ochalek.   

Abstract

Economic evaluation of health-related projects requires principles and methods to address the various trade-offs that need to be made between costs and benefits, across sectors and social objectives, and over time. Existing guidelines for economic evaluation in low- and middle-income countries embed implicit assumptions about expected changes in the marginal cost per unit of health produced by the healthcare sector, the consumption value of health and the appropriate discount rates for health and consumption. Separating these evaluation parameters out requires estimates for each country over time, which have hitherto been unavailable. We present a conceptual economic evaluation framework that aims to clarify the distinct roles of these different evaluation parameters in evaluating a health-related project. Estimates for each are obtained for each country and in each time period, based on available empirical evidence. Where existing estimates are not available, for future values of the marginal cost per unit of health produced by the healthcare sector, new estimates are obtained following a practical method for obtaining projected values. The framework is applied to a simple, hypothetical, illustrative example, and the results from our preferred approach are compared against those obtained from other approaches informed by the assumptions implicit within existing guidelines. This exposes the consequences of applying such assumptions, which are not supported by available evidence, in terms of potentially sub-optimal decisions. In general, we find that applying existing guidelines as done in conventional practice likely underestimates the value of health-related projects on account of not allowing for expected growth in the marginal cost per unit of health produced by the healthcare sector.
© The Author(s) 2021. Published by Oxford University Press in association with The London School of Hygiene and Tropical Medicine.

Entities:  

Keywords:  Cost-effectiveness analysis; benefit–cost analysis; economic growth; global health; low-income countries; middle-income countries

Mesh:

Year:  2022        PMID: 34410385      PMCID: PMC8757497          DOI: 10.1093/heapol/czab104

Source DB:  PubMed          Journal:  Health Policy Plan        ISSN: 0268-1080            Impact factor:   3.344


  26 in total

1.  Discounting and decision making in the economic evaluation of health-care technologies.

Authors:  Karl Claxton; Mike Paulden; Hugh Gravelle; Werner Brouwer; Anthony J Culyer
Journal:  Health Econ       Date:  2010-05-12       Impact factor: 3.046

2.  Determinants of Change in the Cost-effectiveness Threshold.

Authors:  Mike Paulden; James O'Mahony; Christopher McCabe
Journal:  Med Decis Making       Date:  2016-09-27       Impact factor: 2.583

3.  The International Decision Support Initiative Reference Case for Economic Evaluation: An Aid to Thought.

Authors:  Thomas Wilkinson; Mark J Sculpher; Karl Claxton; Paul Revill; Andrew Briggs; John A Cairns; Yot Teerawattananon; Elias Asfaw; Ruth Lopert; Anthony J Culyer; Damian G Walker
Journal:  Value Health       Date:  2016-12       Impact factor: 5.725

4.  Estimating a cost-effectiveness threshold for the Spanish NHS.

Authors:  Laura Vallejo-Torres; Borja García-Lorenzo; Pedro Serrano-Aguilar
Journal:  Health Econ       Date:  2017-12-28       Impact factor: 3.046

5.  Estimating the Reference Incremental Cost-Effectiveness Ratio for the Australian Health System.

Authors:  Laura Catherine Edney; Hossein Haji Ali Afzali; Terence Chai Cheng; Jonathan Karnon
Journal:  Pharmacoeconomics       Date:  2018-02       Impact factor: 4.981

6.  Future and potential spending on health 2015-40: development assistance for health, and government, prepaid private, and out-of-pocket health spending in 184 countries.

Authors: 
Journal:  Lancet       Date:  2017-04-19       Impact factor: 79.321

7.  Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses: Second Panel on Cost-Effectiveness in Health and Medicine.

Authors:  Gillian D Sanders; Peter J Neumann; Anirban Basu; Dan W Brock; David Feeny; Murray Krahn; Karen M Kuntz; David O Meltzer; Douglas K Owens; Lisa A Prosser; Joshua A Salomon; Mark J Sculpher; Thomas A Trikalinos; Louise B Russell; Joanna E Siegel; Theodore G Ganiats
Journal:  JAMA       Date:  2016-09-13       Impact factor: 56.272

8.  Country-Level Cost-Effectiveness Thresholds: Initial Estimates and the Need for Further Research.

Authors:  Beth Woods; Paul Revill; Mark Sculpher; Karl Claxton
Journal:  Value Health       Date:  2016-12       Impact factor: 5.725

9.  Cost-effectiveness thresholds: pros and cons.

Authors:  Melanie Y Bertram; Jeremy A Lauer; Kees De Joncheere; Tessa Edejer; Raymond Hutubessy; Marie-Paule Kieny; Suzanne R Hill
Journal:  Bull World Health Organ       Date:  2016-09-19       Impact factor: 9.408

10.  The marginal benefits of healthcare spending in the Netherlands: Estimating cost-effectiveness thresholds using a translog production function.

Authors:  Niek Stadhouders; Xander Koolman; Christel van Dijk; Patrick Jeurissen; Eddy Adang
Journal:  Health Econ       Date:  2019-08-30       Impact factor: 3.046

View more
  1 in total

1.  Estimating the global demand curve for a leishmaniasis vaccine: A generalisable approach based on global burden of disease estimates.

Authors:  Sakshi Mohan; Paul Revill; Stefano Malvolti; Melissa Malhame; Mark Sculpher; Paul M Kaye
Journal:  PLoS Negl Trop Dis       Date:  2022-06-13
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.